NPM-ALK-dependent CEBPB gene expression

Stable Identifier
R-HSA-9725357
Type
Reaction [BlackBoxEvent]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

CEBPB is a transcription factor with roles in immune and inflammatory reponses that was identified as a target of NPM-ALK signaling downstream of STAT3 and MAPK1/3. CEBPB expression is downregulated after treatment of cells with anti-NPM-ALK RNAi. CEBPB expression downstream of NPM-ALK signaling promotes cellular survival, as its knockdown increases the proportion of cells undergoing apoptosis. In mouse models of NPM-ALK, CEBPB is required for entry into S phase and contributes to the transforming properties of the fusion protein (Piva et al, 2006; reviewed in Hallberg and Palmer, 2013).

Literature References
PubMed ID Title Journal Year
17111047 Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes

Chiarle, R, Piva, R, Inghirami, G, Ruggeri, BA, Boccalatte, F, Cheng, M, Palestro, G, Costa, G, Lombardi, L, Pellegrino, E, Neri, A, Agnelli, L, Mattioli, M

J Clin Invest 2006
24060861 Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Palmer, RH, Hallberg, B

Nat. Rev. Cancer 2013
Participants
Participates
This event is regulated
Disease
Name Identifier Synonyms
anaplastic large cell lymphoma DOID:0050744
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!